Clini Cancer Research: Total transcriptomic sequencing analysis of tumor tissue after Hu14.18-IL2 immunotherapy identification of prognostic biomarkers

Objective: Richard KYang et alanalyzed the whole transcriptomic sequencing data of tumors in 23 stage III-IV melanoma patients in a pilot trial of the anti-GD2immunoasticfactor hu14.18-IL2 to identify the predictable immunoandal and/or tumor biomarkers of melanoma patients with high recurrence riskdesign: the patients were randomly divided into two groups, group A patients received the first course of hu14.18-IL2 immunotherapy (a total of 3 courses) before surgical excision, and group B patients underwent a course of hu14.18-IL2 immunotherapy after surgeryresults: The level of tumor-immersed lymphocytes (TTL) in the removal of tumor tissue in Group A patients was directly related to non-recurrence survival (RFS) and overall survival (OS), and early remission to immunotherapy could also be assessedTIL levels are directly related to previously reported immune characteristics associated with RFS and OS, especially in Group AIn group A patients who removed tumor tissue, RNA transcription levels of cell cycle genes decreased, but RNA levels of DNA repair and gene growth-related genes increasedThe researchers also found that patient prognosis (RFS and OS) were directly related to several immune characteristics and immune-related RNA transcription levels, and negatively related to several tumor growth-related transcripts, especially in Group AMost of the above correlations were not observed in group B tumorsConclusion: This study shows that shortly after the start of hu14.18-IL2 treatment, the immune and tumor cell processes detected through RNA sequencing analysis are associated with the patient's long-term prognosis, and the removal of these RNA in tumor specimens after new assisted immunotherapy may be used as biomarkers for the patient's prognosticcondition